Relieves inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. ANDA 205373, held by Encube. Triamcinolone Acetonide.
As of Nov 15, 2026, ANDA 205373 (Triamcinolone Acetonide), held by Encube, was first approved by FDA on May 13, 2016, with 0 approved supplements and 0 published complete response letters.
INDICATIONS & USAGE Triamcinolone Acetonide Ointment is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 13, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Triamcinolone Acetonide0.1% · ointment;topical | Triamcinolone Acetonide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
